Antonio Recchiuti

Prof. Antonio Recchiuti

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKSriram Krishnamoorthy
Sriram Krishnamoorthy
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
NCNan Chiang
Nan Chiang
SYStephanie Yacoubian
Stephanie Yacoubian
CLChih-Hao Lee
Chih-Hao Lee
CSCharles Serhan
Charles Serhan
Endogenous mechanisms that act in the resolution of acute inflammation are essential for host defense and the return to homeostasis. Resolvin D1 (RvD1), biosynthesized during resolution, displays potent and stereoselective anti-inflammatory actions, such as limiting neutrophil infiltration and proresolving actions. Here, we demonstrate that RvD1 actions on human polymorphonuclear leukocytes (PMNs) are pertussis toxin sensitive, decrease actin polymerization, and block LTB 4 -regulated adhesion molecules (β2 integrins). Synthetic [ 3 H]-RvD1 was prepared, which revealed specific RvD1 recognition sites on human leukocytes. Screening systems to identify receptors for RvD1 gave two candidates—ALX, a lipoxin A 4 receptor, and GPR32, an orphan—that were confirmed using a β-arrestin-based ligand receptor system. Nuclear receptors including retinoid X receptor-α and peroxisome proliferator-activated receptor-α, -δ, -γ were not activated by either resolvin E1 or RvD1 at bioactive nanomolar concentrations. RvD1 enhanced macrophage phagocytosis of zymosan and apoptotic PMNs, which increased with overexpression of human ALX and GPR32 and decreased with selective knockdown of these G-protein-coupled receptors. Also, ALX and GPR32 surface expression in human monocytes was up-regulated by zymosan and granulocyte-monocyte–colony-stimulating factor. These results indicate that RvD1 specifically interacts with both ALX and GPR32 on phagocytes and suggest that each plays a role in resolving acute inflammation.

16 July 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XCXuefen Chen
Xuefen Chen
IBIros Barozzi
Iros Barozzi
ATAlberto Termanini
Alberto Termanini
EPElena Prosperini
Elena Prosperini
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
GNGioacchino Natoli
Gioacchino Natoli
Histone deacetylases (HDACs) regulate inflammatory gene expression, as indicated by the potent antiinflammatory activity of pan-HDAC inhibitors. However, the specific contribution of each of the 11 HDAC proteins to the inflammatory gene expression program is unknown. Using an integrated genomic approach, we found that Hdac3-deficient macrophages were unable to activate almost half of the inflammatory gene expression program when stimulated with LPS. A large part of the activation defect was attributable to loss of basal and LPS-inducible expression of IFN-β, which maintains Stat1 protein levels in unstimulated cells and acts in an autocrine/paracrine manner after stimulation to promote a secondary wave of Stat1-dependent gene expression. Loss of Hdac3-mediated repression of nuclear receptors led to hyperacetylation of thousands of genomic sites and associated gene derepression. The up-regulation of the constitutively expressed prostaglandin endoperoxide synthase, Ptgs1 (Cox-1), a nuclear receptor target, had a causative role in the phenotype because its chemical inhibition reverted, albeit partially, the Ifn-β activation defect. These data indicate a central role for Hdac3 in inflammation and may have relevance for the use of selective Hdac inhibitors as antiinflammatory agents.

18 October 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
SKSriram Krishnamoorthy
Sriram Krishnamoorthy
GFGabrielle Fredman
Gabrielle Fredman
NCNan Chiang
Nan Chiang
CSCharles Serhan
Charles Serhan
Mechanisms controlling resolution of acute inflammation are of wide interest. Here, we investigated microRNAs (miRNAs) in self‐limited acute inflammatory exudates and their regulation by resolvin D1 (RvD1). Using real‐time PCR analysis, we found in resolving exudates that miR‐21, miR‐146b, miR‐208a, miR‐203, miR‐142, miR‐302d, and miR‐219 were selectively regulated ( P <0.05) in self‐limited murine peritonitis. RvD1 (300 ng/mouse or 15 µgkg ‐1 ) reduced zymosan‐elicited neutrophil infiltration into the peritoneum 25–50% and shortened the resolution interval (ß i )by ~4 h. In peritonitis at 12 h, RvD1 up‐regulated miR‐21, miR‐146b, and miR‐219 and down‐regulated miR‐208a in vivo. In human macrophages overexpressing recombinant RvD1 receptors ALX/FPR2 or GPR32, these same miRNAs were significantly regulated ( P <0.05) by RvD1 at concentrations as low as 10 nM, recapitulating the in vivo circuit. In addition, RvD1‐miRNAs identified herein target cytokines and proteins involved in the immune system, e.g. , miR‐146b targeted NF‐κB signaling, and miR‐219 targeted 5‐lipoxygenase and reduced leukotriene production. RvD1 also reduced nuclear translocation of NF‐κB and SMAD and down‐regulated phospho‐IκB. Taken together, these results indicate that resolvin‐regulated specific miR‐NAs target genes involved in resolution and establish a novel resolution circuit involving RvD1 receptor‐dependent regulation of specific miRNAs.—Recchiuti, A., Krishnamoorthy, S., Fredman, G., Chiang, N., and Serhan, C. N. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1‐miRNA circuits. FASEB J. 25, 544–560 (2011). www.fasebj.org

1 January 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TOTaisuke Ohira
Taisuke Ohira
MAMakoto Arita
Makoto Arita
KOKazuhiro Omori
Kazuhiro Omori
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
TDThomas E. Van Dyke
Thomas E. Van Dyke
CSCharles Serhan
Charles Serhan
Resolvins are endogenous lipid mediators that actively regulate the resolution of acute inflammation. Resolvin E1 (RvE1; (5S,12R,18R)-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid) is an endogenous anti-inflammatory and pro-resolving mediator derived from eicosapentaenoic acid that regulates leukocyte migration and enhances macrophage phagocytosis of apoptotic neutrophils to resolve inflammation. In the inflammatory milieu, RvE1 mediates counter-regulatory actions initiated via specific G protein-coupled receptors. Here, we have identified RvE1-specific signaling pathways initiated by the RvE1 receptor ChemR23. RvE1 stimulated phosphorylation of Akt that was both ligand- and receptor-dependent. RvE1 regulated Akt phosphorylation in a time (0-15 min)- and dose-dependent (0.01-100 nm) manner in human ChemR23-transfected Chinese hamster ovary cells. RvE1 stimulated phosphorylation of both Akt and a 30-kDa protein, a downstream target of Akt, identified using a phospho-Akt substrate antibody. The 30-kDa protein was identified as ribosomal protein S6, a translational regulator, and its phosphorylation was inhibited by a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin) and an ERK inhibitor (PD98059) but not by a p38-MAPK inhibitor (SB203580). Ribosomal protein S6 is a downstream target of the PI3K/Akt signaling pathway as well as the Raf/ERK pathway. In ChemR23-expressing differentiated HL60 cells, RvE1 also stimulated the phosphorylation of ribosomal protein S6. In addition, RvE1 enhanced phagocytosis of zymosan A by human macrophages, which are inhibited by PD98059 and rapamycin (mTOR inhibitor). These results indicate that RvE1 initiates direct activation of ChemR23 and signals receptor-dependent phosphorylation. These phosphorylation-signaling pathways identified for RvE1 receptor-ligand interactions underscore the importance of endogenous pro-resolving agonists in resolving acute inflammation.

1 May 2012 in The American Journal of Pathology
Verified
Journal Article
Open access
SKSriram Krishnamoorthy
Sriram Krishnamoorthy
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
NCNan Chiang
Nan Chiang
GFGabrielle Fredman
Gabrielle Fredman
CSCharles Serhan
Charles Serhan
Resolution of acute inflammation is an active process that involves the biosynthesis of specialized proresolving lipid mediators. Among them, resolvin D1 (RvD1) actions are mediated by two G protein-coupled receptors (GPCRs), ALX/FPR2 and GPR32, that also regulate specific microRNAs (miRNAs) and their target genes in novel resolution circuits. We report the ligand selectivity of RvD1 activation of ALX/FPR2 and GPR32. In addition to RvD1, its aspirin-triggered epimer and RvD1 analogs each dose dependently and effectively activated ALX/FPR2 and GPR32 in GPCR-overexpressing β-arrestin systems using luminescence and electric cell-substrate impedance sensing. To corroborate these findings in vivo, neutrophil infiltration in self-limited peritonitis was reduced in human ALX/FPR2-overexpressing transgenic mice that was further limited to 50% by RvD1 treatment with as little as 10 ng of RvD1 per mouse. Analysis of miRNA expression revealed that RvD1 administration significantly up-regulated miR-208a and miR-219 in exudates isolated from ALX/FPR2 transgenic mice compared with littermates. Overexpression of miR-208a in human macrophages up-regulated IL-10. In comparison, in ALX/FPR2 knockout mice, RvD1 neither significantly reduced leukocyte infiltration in zymosan-induced peritonitis nor regulated miR-208a and IL-10 in these mice. Together, these results demonstrate the selectivity of RvD1 interactions with receptors ALX/FPR2 and GPR32. Moreover, they establish a new molecular circuit that is operative in the resolution of acute inflammation activated by the proresolving mediator RvD1 involving specific GPCRs and miRNAs.

1 February 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SOSungwhan F. Oh
Sungwhan F. Oh
PPPadmini S. Pillai
Padmini S. Pillai
Antonio RecchiutiAntonio Recchiuti
Antonio Recchiuti
RYRong Yang
Rong Yang
CSCharles Serhan
Charles Serhan
E-series resolvins are antiinflammatory and pro-resolving lipid mediators derived from the ω-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) that actively clear inflammation to promote tissue homeostasis. Aspirin, in addition to exerting antithrombotic actions, also triggers the biosynthesis of these specialized pro-resolving mediators. Here, we used metabolomic profiling to investigate the biosynthesis of E-series resolvins with specific chiral chemistry in serum from human subjects and present evidence for new 18S series resolvins. Aspirin increased endogenous formation of 18S-hydroxyeicosapentaenoate (18S-HEPE) compared with 18R-HEPE, a known resolvin precursor. Human recombinant 5-lipoxygenase used both enantiomers as substrates, and recombinant LTA4 hydrolase (LTA4H) converted chiral 5S(6)-epoxide–containing intermediates to resolvin E1 and 18S-resolvin E1 (RvE1 and 18S-RvE1, respectively). 18S-RvE1 bound to the leukocyte GPCRs ChemR23 and BLT1 with increased affinity and potency compared with the R-epimer, but was more rapidly inactivated than RvE1 by dehydrogenase. Like RvE1, 18S-RvE1 enhanced macrophage phagocytosis of zymosan, E. coli, and apoptotic neutrophils and reduced both neutrophil infiltration and proinflammatory cytokines in murine peritonitis. These results demonstrate two parallel stereospecific pathways in the biosynthesis of E-series resolvins, 18R- and 18S-, which are antiinflammatory, pro-resolving, and non-phlogistic and may contribute to the beneficial actions of aspirin and ω-3 polyunsaturated fatty acids.